<?xml version="1.0" encoding="UTF-8"?>
<p id="Par43">For MERS, despite many studies in humans, there is no consensus on the best treatment; thus, randomized clinical trials are needed to assess potential treatment options.
 <sup>
  <xref ref-type="bibr" rid="CR134">134</xref>
 </sup> Several therapeutics are in development, including convalescent plasma, lopinavir/ritonavir, ribavirin, IFN and novel therapies, including polyclonal antibodies and broad-spectrum antivirals.
 <sup>
  <xref ref-type="bibr" rid="CR108">108</xref>
 </sup> Antimicrobial peptides (AMPs) may be used as alternative therapeutic agents,
 <sup>
  <xref ref-type="bibr" rid="CR135">135</xref>
 </sup> and many have been effective even against bacterial proteases agents.
 <sup>
  <xref ref-type="bibr" rid="CR136">136</xref>
 </sup> Antiviral drugs with effective activity in vitro include neutralizing monoclonal antibodies, antiviral peptides, mycophenolic acid, lopinavir, IFN, ribavirin, nitazoxamide, mycophenolate mofetil (MMF), alisporivir, silvestro, and corticosteroids.
 <sup>
  <xref ref-type="bibr" rid="CR19">19</xref>,
  <xref ref-type="bibr" rid="CR21">21</xref>,
  <xref ref-type="bibr" rid="CR59">59</xref>
 </sup>
</p>
